Urokinase-type plasminogen activator in colorectal cancer: Relationship with clinicopathological features and patient outcome

Clinical Cancer Research

Volumn 3, Issue 10, 1997, Pages 1837-1840

  Skelly, Maeve M ^a   Troy, Alice ^a   Duffy, Michael J ^a   Mulcahy, Hugh E ^a   Duggan, Catherine ^a   Connell, Thomas G ^a   O'Donoghue, Diarmuid P ^a   Sheahan, Kieran ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

UROKINASE;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER SURVIVAL; COLON BIOPSY; COLORECTAL CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION;

ADENOCARCINOMA; ADENOMATOUS POLYPS; ADULT; AGED; AGED, 80 AND OVER; COLONIC POLYPS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; INTESTINAL MUCOSA; LIFE TABLES; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; RISK; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; URINARY PLASMINOGEN ACTIVATOR; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 0030801567     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Dano, K., Andreasen, P. A., Grondahl-Hansen, J., Kristensen, P., Nielsen, L. S., and Skriver, L. Plasminogen activators, tissue degradation and cancer. Adv. Cancer Res., 44: 139-266, 1985.
2. Duffy, M. J. Role of proteolytic enzymes in cancer invasion and metastasis. Clin. Exp. Metastasis, 10: 145-155, 1992.
3. Schmitt, M., Janicke, F., and Graeff, H. Tumour-associated proteases. Fibrinolysis., 6 (Suppl. 4): 3-26, 1992.
4. Aznavoorian, S., Murphy, A. N., Stetler-Stevenson, W. G., and Liotta, L. Molecular aspects of tumour cell invasion and metastasis. Cancer (Phila.), 71: 1368-1383, 1993.
5. Schmitt, M., Janicke, F., Chucholowski, N., Goretzki, L., Moniwa, N., Schuren, E., Wilhelm, O., and Graeff, H. Biological and clinical relevance of the urokinase-type plasminogen activator (u-PA) in breast cancer. Biomed. Biochim. Acta., 50: 737-741, 1991.
6. Janicke, F., Schmitt, M., Ulm, K., Gossner, W., and Graeff, H. Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Lancet, 2: 1049, 1989.
7. Duffy, M. J., O'Grady, P., Devaney, D., O'Siorain, L., Fennelly, J. J., and Lijnen, H. J. Urokinase-plasminogen activator, a marker for aggressive breast cancers. Cancer (Phila.), 62: 531-533, 1988.
8. Chung, S. M. Variant cathepsin L activity from gastric cancer tissue. Jpn. J. Cancer Res., 81: 813-819, 1990.
9. de Bruin, P. A., Verspaget, H. W., Griffioen, G., Verheijen, J. H., Dooijewaard, G., and Lamers, C. B. Plasminogen activators in endoscopic biopsies as indicators of gastrointestinal cancer: comparison with resection specimens. Br. J. Cancer, 60: 397-400, 1989.
10. Nekarda, H., Schmitt, M., Ulm, K., Wenninger, A., Vogelsang, H., Becker, K., Roder, J. D., Fink, U., and Siewert, J. R. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res., 54: 2900-2907, 1994.
11. Caslen, B., Gustavsson, B., and Astedt, B. Cell membrane receptors for urokinase plasminogen activator are increased in malignant ovarian tumours. Eur. J. Cancer. 27: 1445-1448, 1991.
12. Camiolo, S. M., Markus, G., and Piver, M. S. Plasminogen activator content of gynecological tumours and their metastases. Gynecol. Oncol., 26: 364-373, 1987.
13. Kirchheimer, J. C., Koller, A., and Binder, B. R. Isolation and characterization of plasminogen activators from hyperplastic and malignant prostate tissue. Biochim. Biophys Acta., 797: 256-265, 1988.
14. Camiolo, S. M., and Greco, W. R. Plasminogen activator content of human tumour and adjacent normal tissue measured with fibrin and non-fibrin assays. Cancer Res., 46: 1788-1794, 1986.
15. Hienert, G., Kirchheimer, J. C., Pfluger, H., and Binder, B. R. Urokinase-type plasminogen activator as a marker for the formation of distant metastases in prostatic carcinomas. J. Urol., 140: 1466-1469, 1988.
16. De Bruin, P. A., Griffioen, G., Verspaget, H. W., Verheijen, J. H., Dooijewaard, G., van den Ingh, H. F., and Lamers, C. B. H. W. Plasminogen activator profiles in neoplastic tissues of the human colon. Cancer Res., 48: 4520-4524, 1988.
17. Harvey, S. R., Lawerence, D. D., Madeja, J. M., Abbey, S. J., and Markus, G. Secretion of plasminogen activators by human colorectal and gastric tumour explants. Clin. Exp. Metastasis, 6: 431-450, 1988.
18. Ganesh, S., Sier, C. F. M., Griffioen, G., Vlodgraven, H. J. M., de Boer, A., Welvaart, K., van de Velde, C. J. H., van Krieken, J. H. J. M., Verheijen, J. H., Lamers, C. B. H. W., and Verspaget, H. W. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res., 54: 4065-4071, 1994.
19. Sheahan, K., Shuja, S., and Murnane, M. J. Cysteine protease activities and tumour development in human colorectal carcinoma. Cancer Res, 49: 3809-3814, 1989.
20. Duffy, M. J., Proteases as prognostic markers in cancer. Clin. Caner Res., 2: 613-618, 1996.
21. Mulcahy, H. E., Duffy, M. J., Gibbons, D., McCarthy, P., Parfrey, N. A., O'Donoghue, D. P., and Sheahan, K. Urokinase-type plasminogen activator and outcome in Duke's B colorectal cancer. Lancet. 344: 583-584, 1994.
22. Davis, N. C., and Newland, R. C. Terminology and classification of colorectal carcinoma: the Australian clinico-pathological staging system. Aust. N. Z. J. Surg., 53: 211-221, 1983.
23. Cuzick, J. A Wilcoxon-type test for trend. Stat. Med., 4: 87-89, 1985.
24. Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., and Smith, P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br. J. Cancer, 35: 1-39, 1977.
25. Kalbfleisch, J. D., and Prentice, R. L. The Statistical Analysis of Failure Time Data. New York: John Wiley & Sons, Inc., 1988.
26. de Bruin, P. A., Griffioen, G., Verspaget, H. W., Verheijen, J. H., and Lamers, C. B. Plasminogen activators and tumour development in the human colon: activity levels in normal mucosa, adenomatous polyps and adenocarcinomas. Cancer Res., 47: 4654-4657, 1987.
27. Pepper, M. S., Vassalli, J-D., Montesano, R., and Orci, L. Urokinase-type plasminogen activator is induced in migrating capillary endothelial cells. J. Cell. Biol., 105: 2535-2541, 1987.
28. Pepper, M. S., Sappino, A-P., Stocklin, R., Montesano, R., Orci, L., and Vassalli, J. H-D. Upregulation of urokinase receptor expression on migrating endothelial cells. J. Cell. Biol., 122: 673-684, 1993.
29. Pepper, M. S., Sappino, A-P., Montesano, R., Orci, L., and Vassalli, J. H-D. Plasminogen activator inhibitor 1 is induced in migrating endothelial cells. J. Cell Physiol., 153: 129-139, 1992.
30. Shapiro, R. L., Duquette, J. G. Roses, D. F., Nunes, I., Harris, M. N., Kamino, H., Wilson, E. L., and Rifkin, D. B. Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (u-PA)-deficient and wild type mice: cellular blue nevi invade but do not progress to malignant melanoma in u-PA deficient animals. Cancer Res., 56; 3597-3604, 1996.
31. Saksela, O., and Rifkin, D. B. Cell-associated plasminogen activation: regulation and physiological functions. Annu. Rev. Cell Biol., 4: 93-126, 1988.
32. Murphy, G., Reynolds, J. J., and Hembry, R. M. Metalloproteases and cancer invasion and metastasis. Int. J. Cancer, 44: 757-760, 1989.
33. Chapuis, P. H., Dent, O. F., Fisher, R., Newland, R. C., Pheils, M. T., Smyth, E., and Colquhoun, K. A multivariate analysis of clinical and pathological variables in prognosis after resection of large bowel cancer. Br. J. Surg., 72: 698-702, 1985.
34. Mueller, B. M., Yu, Y. B., and Laug, W. E. Overexpression of plasminogen activator inhibitor 2 in human melanoma cells inhibits spontaneous metastasis in scid/scid mice. Proc. Natl. Acad. Sci. USA, 92: 205-209, 1995.
35. Kobayashi, H., Gotoh, J., Fujie, M., Shinohara, H., Moniwa, N., and Terao, T. Inhibition of metastasis of Lewis lung carcinoma by a synthetic peptide within growth factor-like domain of urokinase in the experimental and spontaneous metastasis model. Int. J. Cancer, 57: 727-733, 1994.
36. Sledge, G., Jr., Qulali, M., Goulet, R., Bone, E. A., and Fife, R. Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J. Natl. Cancer Inst., 87: 1546-1550, 1995.
37. Watson, S. A., Morris, T. M., Robinson, G., Crimmin, M. J., Brown, P. D., and Hardcastle, J. D. Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res., 55: 3629-3633, 1995.